SharpyWegovy Heart Failure: Is It FDA Approved? Trials and Coverage
No. As of its June 2026 label, Wegovy (semaglutide) is not FDA approved to treat heart failure. It is approved to lower the risk of heart attack, stroke and heart death in adults with heart disease and excess weight, for weight loss, and for MASH. In two trials of people with obesity and heart failure with preserved ejection fraction (STEP-HFpEF), Wegovy eased symptoms and helped people walk farther than placebo. Ask your cardiologist whether it fits your case, and use Sharpy to keep muscle while you lose weight.
Is Wegovy approved for heart failure? No. The current FDA label for Wegovy (semaglutide), dated June 2026, does not include heart failure. Wegovy is approved to cut the risk of heart attack, stroke and heart death in adults with heart disease and excess weight, for long-term weight loss, and for MASH liver disease. Two large trials did show that Wegovy eased symptoms in people with obesity and one common type of heart failure. That is real evidence, but it is not an approved use in the US.
This guide explains what the label says, what the trials found, how Zepbound compares, and what it means for coverage. It is not a guide to treating heart failure. Every heart failure decision belongs to your cardiologist.
Is Wegovy FDA approved for heart failure?
Not yet. Here is what the June 2026 Wegovy prescribing information lists for the injection:
| Wegovy use | FDA approved? |
|---|---|
| Lower the risk of heart attack, stroke or heart death in adults with heart disease and obesity or overweight | Yes |
| Long-term weight loss (adults and kids 12 and older with obesity, adults with overweight plus a related condition) | Yes |
| MASH (fatty liver inflammation) with moderate to advanced scarring | Yes, accelerated approval |
| Heart failure, including heart failure with preserved ejection fraction (HFpEF) | No |
Novo Nordisk did ask the FDA to add heart failure. In August 2024 it withdrew that filing and said it would come back with more data, including from its FLOW kidney trial. As of November 2026 the label still has no heart failure indication, and we could not find an FDA decision on a new filing. In Europe, regulators backed a 2024 update that adds the heart failure trial results to the Wegovy product information. That describes the data. It is not a separate heart failure approval.
What kind of heart failure was studied?
Heart failure does not mean the heart has stopped. It means the heart cannot keep up with what the body needs. Doctors split it by ejection fraction, the share of blood the main pumping chamber pushes out with each beat.
- Reduced ejection fraction (HFrEF): the heart muscle is weak and squeezes poorly.
- Preserved ejection fraction (HFpEF): the heart squeezes fine but is stiff and does not fill well. Doctors also call it diastolic heart failure.
The Wegovy trials only studied HFpEF in people with a BMI of 30 or more. This "obesity HFpEF" type is common, and extra weight seems to drive a lot of the symptoms: tiredness, short breath and swollen legs. There is much less evidence for GLP-1 drugs in the weak-muscle type (HFrEF), so the trial results below should not be stretched to cover it.
What the Wegovy heart failure trials found
Novo Nordisk ran two 52-week trials, both comparing Wegovy 2.4 mg once a week with a placebo shot. Both were published in the New England Journal of Medicine.
| Result at 1 year | STEP-HFpEF (no diabetes) | STEP-HFpEF DM (with type 2 diabetes) |
|---|---|---|
| People in trial | 529 | 616 |
| Symptom score change (KCCQ, higher is better) | +16.6 Wegovy vs +8.7 placebo | +13.7 Wegovy vs +6.4 placebo |
| Weight change | -13.3% vs -2.6% | -9.8% vs -3.4% |
| Extra distance walked in 6 minutes vs placebo | 20.3 meters | 14.3 meters |
| Inflammation marker (CRP) | -43.5% vs -7.3% | Lower than placebo |
| Serious side effects | 13.3% vs 26.7% | 17.7% vs 28.8% |
In plain English: people on Wegovy felt better, did more in daily life, walked farther and lost much more weight than people on placebo. Serious problems were less common on Wegovy than on placebo in both trials.
What the trials did not prove: they were not built to show that Wegovy prevents heart failure hospital stays or deaths. Their main goals were symptoms and weight. A 2026 review of 14 trials in the journal Drugs found fewer heart failure hospital stays with GLP-1 drugs in HFpEF, but pooled data like that is not the same as a dedicated outcomes trial.
Wegovy vs Zepbound for heart failure
Lilly ran a different kind of trial with tirzepatide (Zepbound, Mounjaro). SUMMIT looked at hard events, not just symptoms.
| Wegovy (STEP-HFpEF) | Zepbound (SUMMIT) | |
|---|---|---|
| Drug and dose | Semaglutide 2.4 mg weekly | Tirzepatide up to 15 mg weekly |
| People | 529 (no diabetes) | 731 (with or without diabetes) |
| Main goals | Symptoms and weight | Heart death or worsening heart failure, plus symptoms |
| Worsening heart failure or heart death | Not a main goal | 9.9% vs 15.3% on placebo (38% lower risk) |
| Symptom score gain vs placebo | 7.8 points | 6.9 points |
| FDA approved for heart failure? | No | No |
Most of SUMMIT's benefit came from fewer worsening heart failure events. Heart deaths were few in both groups (8 vs 5) and the difference was not meaningful. Neither drug has a US heart failure label. The trials were also run in different people, so you cannot rank the two drugs from these numbers. For a full side-by-side, see semaglutide vs tirzepatide.
Why weight loss may ease heart failure symptoms
Researchers think several things help at once. Less body fat means less work for the heart. Inflammation drops, which the CRP results suggest. Blood pressure tends to fall. Some people also carry less fluid, and a STEP-HFpEF analysis reported less need for loop diuretics (water pills) on semaglutide. Do not change any heart medicine on your own, though. That is a call for your heart team.
There is one catch. GLP-1 drugs take weight from muscle as well as fat. For someone with heart failure, leg strength matters a lot, because weak legs make every walk harder. Studies of heart size on these drugs are covered in our guide to GLP-1 heart muscle loss.
This is where protein and simple strength work earn their place. With your doctor's okay, a daily protein target and short, gentle resistance sessions help you keep the muscle you need for walking and stairs. Sharpy gives you one protein target, one 20-minute workout and one Shape Score each day, so you can see whether you are losing fat rather than strength. Our protein target guide explains how to set the number.
Wegovy heart failure safety: what the label says to watch
These label warnings matter most if you have a heart condition:
- Heart rate increase. Wegovy can raise resting heart rate. The label tells doctors to check it at regular visits. Tell your care team if your heart races at rest.
- Kidney injury from fluid loss. Vomiting, diarrhea or not drinking enough can dry you out and hurt your kidneys. This matters more if you take water pills.
- Stomach side effects. Nausea and vomiting are common early on and can be severe.
Call your doctor right away for new or worse shortness of breath, fast weight gain from fluid, swelling in your legs, or chest pain. Those can be heart failure signs, not drug side effects.
Is Wegovy covered for heart failure?
Coverage follows the label. Since heart failure is not an approved use, a plan is unlikely to cover Wegovy for heart failure alone. Many people with HFpEF qualify another way:
- Heart disease: if you have had a heart attack, stroke or have other heart disease plus overweight or obesity, the heart-event indication may apply. See does Medicare cover Wegovy.
- Medicare GLP-1 Bridge: Medicare.gov lists a BMI of 30 or more plus diastolic heart failure as one way to qualify. Details are in our Medicare GLP-1 Bridge guide.
- Weight loss: commercial plans that cover weight-loss drugs may cover it for obesity.
Ask your prescriber which approved use fits your chart. That is what the prior authorization will hinge on.
Questions to ask your cardiologist
- Is my heart failure the preserved (HFpEF) or reduced (HFrEF) type?
- Do the STEP-HFpEF or SUMMIT results apply to someone like me?
- Which approved use would my plan accept for Wegovy or Zepbound?
- Should my water pill or blood pressure pills be watched more closely as I lose weight?
- How much protein and what kind of exercise are safe for me?
If you are pregnant, under 18, or have a history of an eating disorder, talk to your doctor before any weight-loss drug.
Heart failure plus a GLP-1 is a team effort with your doctor. Your part is the daily basics: protein, gentle strength work and steady tracking. Sharpy keeps those to one target, one workout and one score a day.
Sources
- Wegovy injection and tablets prescribing information (June 2026), DailyMed
- Zepbound prescribing information (September 2026), DailyMed
- Kosiborod et al., Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity, NEJM 2023 (PubMed 37622681)
- Kosiborod et al., Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes, NEJM 2024 (PubMed 38587233)
- Packer et al., Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT), NEJM 2025 (PubMed 39555826)
- Yuan et al., GLP-1 Receptor Agonists in Heart Failure: Systematic Review and Meta-analysis, Drugs 2026 (PubMed 42791433)
- Semaglutide and diuretic use in obesity-related HFpEF: pooled STEP-HFpEF analysis (PMC11400859)
- Novo Nordisk withdraws bid for Wegovy label expansion in heart failure, Pharma Manufacturing (Aug 2024)
- European drug agency supports Wegovy label update for obesity-related heart failure, Yahoo Finance (Sep 2024)
- Medicare.gov: Weight loss drugs (GLP-1 Bridge)
Questions people ask
Is Wegovy FDA approved for heart failure?
No. The Wegovy prescribing information on DailyMed (June 2026) lists three uses for the injection: lowering the risk of major heart events in adults with heart disease and obesity or overweight, long-term weight loss, and MASH liver disease. Heart failure is not one of them. Novo Nordisk withdrew its US heart failure filing in August 2024 and said it would resubmit with more data. We found no FDA decision since then.
What did the Wegovy heart failure trial show?
STEP-HFpEF gave 529 adults with heart failure with preserved ejection fraction and a BMI of 30 or more Wegovy 2.4 mg or placebo for 52 weeks. Symptom scores improved 16.6 points on Wegovy versus 8.7 on placebo, weight fell 13.3% versus 2.6%, and walking distance in 6 minutes rose 21.5 meters versus 1.2 meters (NEJM 2023). A second trial in people who also had type 2 diabetes found similar but smaller gains.
Can you take Wegovy if you have congestive heart failure?
Heart failure is not listed as a reason you cannot take Wegovy, and the STEP-HFpEF trials enrolled people with heart failure. But the trials studied one type (preserved ejection fraction) in people with obesity. If you have heart failure, the choice belongs to your cardiologist, who will look at your type of heart failure, your kidneys and your water pills.
Is Wegovy covered for heart failure?
Insurance plans cover Wegovy for its FDA-approved uses, so heart failure alone usually is not a covered reason. Wegovy is often covered for its heart-event indication if you have heart disease. Medicare.gov lists a BMI of 30 or more plus diastolic heart failure as one way to qualify for the Medicare GLP-1 Bridge.
Is Zepbound approved for heart failure?
No. The Zepbound label on DailyMed (September 2026) lists weight loss and moderate to severe obstructive sleep apnea in adults with obesity. In the SUMMIT trial, tirzepatide lowered the risk of heart death or worsening heart failure by 38% versus placebo in people with obesity and preserved ejection fraction, but that is not an FDA-approved use.
Does Wegovy help with heart problems?
Yes, for one approved use. In the SELECT trial, Wegovy lowered the risk of heart attack, stroke or heart death by 20% in adults with heart disease and overweight or obesity, and that benefit is in the label. Its effect on heart failure symptoms comes from trials, not from an approved indication.